In vitro and in vivo activities of a novel cephalosporin, BMS-247243, against organisms other than staphylococci.
BMS-247243, a novel cephalosporin inhibitory for methicillin-resistant staphylococci, primarily has activity against gram-positive bacteria. The activities of BMS-247243, cefotaxime, and ceftriaxone against streptococci and Streptococcus pneumoniae were similar. BMS-247243 inhibits Enterococcus faecalis but not Enterococcus faecium. BMS-247243 also inhibits many inherently vancomycin-resistant species (Leuconstoc, Lactobacillus, Pediococcus) and anaerobic gram-positive bacteria.
Clark
Junius
J
Department of Microbiology, Bristol-Myers Squibb Co., Wallingford, Connecticut 06492, USA.
Fung-Tomc
Joan C
JC
Minassian
Beatrice
B
Tsai
Yuan-Hwang
YH
Yang
Hyekyung
H
Huczko
Elizabeth
E
Kolek
Benjamin
B
Chaniewski
Susan
S
Ferraro
Cheryl
C
Drain
Rebecca
R
Gradelski
Elizabeth
E
Bonner
Daniel P
DP
D000818:Animals; D001419:Bacteria / Q000187:drug effects; D002511:Cephalosporins / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D005260:Female; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology; D006801:Humans; D007165:Immunosuppression Therapy; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D009025:Morpholines / Q000494:pharmacology*; D010403:Penicillin Resistance; D011008:Pneumococcal Infections / Q000188:drug therapy / Q000382:microbiology; D011725:Pyridines / Q000494:pharmacology*; D013997:Time Factors
D002511:Cephalosporins; D009025:Morpholines; D011725:Pyridines; C452864:BMS-247243